- Race Oncology (RAC) receives human ethics approval for the next stage of its clinical trial of Zantrene in breast cancer patients
- The company received the approval from the Hunter New England Human Research Ethics Committee for the observational stage of a planned phase 1/2b cardioprotection clinical program using Zantrene
- The company must now submit and receive research institutional governance approval before patients can be enrolled and treated in the study
- Race says the human trials will be fully funded from its December 2021 capital raise
- Race Oncology is up 3.99 per cent, trading at $1.96 at 2:51 pm AEDT
Race Oncology (RAC) has received human ethics approval for the next stage of its clinical trial of Zantrene in breast cancer patients.
The company received human ethics approval from the Hunter New England Human Research Ethics Committee for the observational stage of a planned phase 1/2b cardioprotection clinical program using its cancer drug, Zantrene.
Race must now submit and then receive research institutional governance approval before patients can be enrolled and treated in the study.
The company said submission is expected to take place within the coming weeks, with approval typically anticipated within eight weeks.
The trial will recruit and monitor up to 50 patients being treated for breast cancer using the standard of care regimen of doxorubicin and cyclophosphamide, which is commonly referred to as “AC chemotherapy”.
The aim of the study will be to identify the rate and level of heart damage caused by AC chemotherapy, using modern advanced cardiac imaging and biochemical methods.
The data from this study will then be used to design a subsequent interventional trial that may help patients to avoid the permanent heart damage caused by AC chemotherapy, as well as potentially improving anti-cancer outcomes.
“This trial is Race’s first step in advancing the cardioprotection opportunity for Zantrene in the clinic,” Race Chief Scientific Officer Dr Daniel Tillett said.
“Gaining high quality observational data to design our interventional phase 1/2b trial of Zantrene in breast cancer is critical to the success of this program.”
Race said these human trials will be fully funded from its December 2021 capital raise.
Race Oncology was up 3.99 per cent, trading at $1.96 at 2:51 pm AEDT.